<DOC>
	<DOCNO>NCT00851903</DOCNO>
	<brief_summary>This study extension LANTU_C_02761 study name EASIE identify NCT00751114 ( core study compare insulin glargine versus sitagliptin insulin-naïve patient treat metformin adequately control ) . All patient Glycosylated Hemoglobin A1c ( HbA1c ) ≥ 7 % end core study possibility enter extension study meet inclusion criterion present exclusion criterion . The visit 14 core study ( week 24 ) visit 1 ( baseline , week 0 ) extension study consist 12-week treatment period . The objective extension study : - To assess glycemic control ( HbA1c &lt; 7 % ) 3-month combination therapy metformin , insulin glargine sitagliptin patient adequately control previous treatment metformin plus either insulin glargine sitagliptin . - To assess effect insulin glargine combination sitagliptin HbA1c level , fast plasma glucose , 7-point glucose profile , hypoglycemia occurrence , body weight overall safety .</brief_summary>
	<brief_title>Evaluation Insulin Glargine Combination With Sitagliptin Type 2 Diabetes Patients : EASIE Extension Trial</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Inclusion criterion : Patients complete core study LANTU_C_02761 ( NCT00751114 ) i.e . go visit 14 investigation , HbA1c &gt; = 7 % , Dose metformin compliant inclusion criterion core study ( i.e . least 1 g/day ) , maintain stable duration core study Ability willingness perform plasma blood glucose monitoring use sponsorprovided plasma glucose meter complete patient dairy , Signed informed consent obtain prior study procedure , Willingness ability comply study protocol . Treatment oral antidiabetic drug metformin sitagliptin core study , Treatment insulin Insulin Glargine core study ( except case emergency , period time le 7 day ) , Treatment nonpermitted drug core study , Pregnant lactate woman , Inpatient care , Active proliferative retinopathy , define photocoagulation vitrectomy occurrence 6 month prior visit 1 , unstable ( rapidly progress ) retinopathy may require photocoagulation surgical treatment study ( optic fundus examination perform within 2 year prior study entry core study ) , Impaired renal function : serum creatinine &gt; = 1.5 mg/dL ( &gt; = 133µmol/L ) &gt; = 1.4 mg/dL ( &gt; =124 µmol/L ) men woman , respectively , History sensitivity study drug drug similar chemical structure , Impaired hepatic function : alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) &gt; 3 x upper limit normal range , Alcohol drug abuse within last year , Night shift worker , Presence condition ( medical , psychological , social geographical ) , current anticipate investigator feel would compromise patient 's safety limit patient successful participation study , Treatment weight loss medication ( e.g . sibutramine , orlistat , rimonabant ) , History pancreatitis .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>